Matthew Biegler
Stock Analyst at Oppenheimer
(3.26)
# 1,044
Out of 5,157 analysts
91
Total ratings
37.8%
Success rate
6.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Outperform | $36 → $50 | $34.74 | +43.93% | 7 | Feb 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $750 → $865 | $772.03 | +12.04% | 1 | Feb 2, 2026 | |
| RLAY Relay Therapeutics | Upgrades: Outperform | $14 | $10.69 | +30.96% | 7 | Jan 26, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $15.76 | +204.57% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $24.49 | +83.75% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $12.59 | +19.14% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $10.19 | +115.90% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $15.90 | +76.10% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.66 | +381.93% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $4.88 | +43.44% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.71 | +232.10% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $16.00 | +900.00% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $13.83 | +225.38% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $148.56 | -22.59% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $34.74 | +52.56% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $3.06 | +553.59% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $8.55 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.01 | +74.78% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $12.90 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.29 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $21.28 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.57 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.39 | - | 2 | Dec 22, 2022 |
Tyra Biosciences
Feb 3, 2026
Maintains: Outperform
Price Target: $36 → $50
Current: $34.74
Upside: +43.93%
Regeneron Pharmaceuticals
Feb 2, 2026
Reiterates: Outperform
Price Target: $750 → $865
Current: $772.03
Upside: +12.04%
Relay Therapeutics
Jan 26, 2026
Upgrades: Outperform
Price Target: $14
Current: $10.69
Upside: +30.96%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $15.76
Upside: +204.57%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $24.49
Upside: +83.75%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $12.59
Upside: +19.14%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $10.19
Upside: +115.90%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $15.90
Upside: +76.10%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.66
Upside: +381.93%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $4.88
Upside: +43.44%
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $2.71
Upside: +232.10%
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $16.00
Upside: +900.00%
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $13.83
Upside: +225.38%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $148.56
Upside: -22.59%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $34.74
Upside: +52.56%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.06
Upside: +553.59%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $8.55
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $8.01
Upside: +74.78%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $12.90
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.29
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $21.28
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.57
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.39
Upside: -